Skip to content
Storytelling Co – Lifestyle
Author:
AusperBio Therapeutics Inc.
AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies
August 27, 2026
AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171
August 3, 2026